Cover -- Title -- Copyright -- Contents -- Foreword -- Acknowledgments -- Contributors -- PART I Principles of Oncology -- Chapter 1 Biology of Cancer -- HYPOXIA -- GLUCOSE AND pH -- VASCULOGENIC MIMICRY -- REFERENCES -- Chapter 2 Evaluation of the Cancer Patient -- MEDICAL HISTORY -- History of Present Illness -- Review of Systems -- Past Medical History -- Family History, Social History and Medications -- PHYSICAL EXAMINATION -- PERFORMANCE STATUS ASSESSMENT -- LABORATORY -- TUMOR MARKERS -- IMAGING -- THE INITIAL CONSULTATION -- REFERENCES -- Chapter 3 Principles of Chemotherapy -- ANTI-NEOPLASTIC AGENTS -- ALKYLATING AGENTS -- NON-CLASSICAL ALKYLATING AGENTS -- Platinum-Containing Compounds -- ANTI-METABOLITES -- Pyrimidine Analogs -- Purine Anti-metabolites -- Guanine Analogs -- Adenosine Analogs -- Folate Antagonists (5) -- ANTIMICROTUBULE AGENTS (6, 7) -- Vinca Alkaloids -- Taxanes -- TOPOISOMERASE INHIBITORS -- Camptothecins (10) -- Epipodophyllotoxin Derivatives -- Anthracyline Derivatives -- HORMONAL AGENTS (TABLE 3.6) -- Selective Estrogen Receptor Modulators (11) -- Aromatase Inhibitors (12) -- Luteinizing Hormone-releasing Hormone -- Agonist and Antagonists -- Anti-androgens -- TYROSINE KINASE INHIBITORS BIOTHERAPY (TABLE 3.8) (TABLE 3.7) Interferon -- BIOTHERAPY (TABLE 3.8) -- Interferon -- Interleukin -- Monoclonal Antibodies (Table 3.9) (19, 20) -- MISCELLANOUS CYTOTOXIC AGENTS -- Immunomodulatory Drugs (21) -- Retinoids DNA Methyltransferase Inhibitors -- Proteasome Inhibitors -- Histone Deacetylase Inhibitors -- DNA Methyltransferase Inhibitors -- REFERENCES -- Chapter 4 Pharmacologic Principles of Regional Therapy in the Treatment of Liver Metastases or Primary Liver Tumors -- PHARMACOLOGIC CONCEPTS USEFUL IN UNDERSTANDING AND EVALUATING POTENTIAL ADVANTAGES OF REGIONAL DELIVERY FOR SPECIFIC DRUGS.

Regional Delivery of the Drug Leads toIncreased Local Concentrations -- Increased Local Concentration Leads to Increased Therapeutic Response -- Regional Delivery of a Drug Leads to Decreased Systemic Exposure -- PHARMACOLOGICAL SUITABILITY FOR HEPATIC ARTERIAL INFUSION OF DIFFERENT ACTIVE DRUGS IN COLORECTAL CANCER -- 5-Fluorouracil -- Irinotecan -- Oxaliplatin -- THERAPEUTIC MONOCLONAL ANTIBODIES -- REGIONAL THERAPY PHARMACOLOGY APPENDIX -- PHARMACOLOGY APPENDIX (51…54) -- REFERENCES -- PART II Principles of Image-Guided Therapies -- Chapter 5 Image-Guided Interventions: Fundamentals of Radiofrequency Tumor ablation -- KEY POINTS -- INTRODUCTION -- THERMAL COAGULATION NECROSIS -- THE BIO-HEAT EQUATION -- PART I: ENERGY DEPOSITED … THE BIO-HEAT EQUATION TECHNOLOGY -- Power Generators and Energy Delivery algorithms -- Multi-tine Applicators -- Multi-applicator Arrays -- Bipolar Arrays -- Internally Cooled Electrodes -- Cluster RF -- Perfused Electrodes -- Pulsed RF Application -- Switching RF Applicator Energy -- Comparison to Other Thermal Sources -- PART II: BIOLOGY AND TISSUE INTERACTIONS -- Effect of Tumor and Background tTissue Characteristics -- Electrical Conductivity -- PART III: OPERATOR AND TECHNIQUE -- Choice of Applicator -- Overlapping Techniques -- Patient Selection -- CONCLUSION -- REFERENCES -- Chapter 6 Principles of Embolization -- EMBOLOTHERAPY -- General Indications -- Embolic Materials -- Embolization: Technical Considerations -- CHEMOEMBOLIZATION -- Synergistic Effects of Ischemia and Drug Therapy -- Chemotherapeutic Agents Used for Chemoembolization -- Lipiodol Chemoembolization -- Lobar Ablation Technique with Both Arterial and Portal Embolization -- REFERENCES -- Chapter 7 Imaging in Interventional Oncology: Role of Image Guidance -- IMAGING FOR PROCEDURE PLANNING -- IMAGING FOR DEVICE DELIVERY.

Advances in Real-time Imaging -- Three-dimensionality -- Contrast Agents Navigation -- Image Fusion -- Navigation -- Robotics -- Open Access -- Radiation Exposure -- INTRA-PROCEDURAL MONITORING -- IMAGING FOR THERAPY ASSESSMENT -- SUMMARY -- REFERENCES -- Chapter 8 Assessment of tumor response on Magnetic Resonance imaging after locoregional therapy -- Role of Imaging in Assessing -- Treatment Response -- MR Imaging Technique -- MR Imaging after Tissue Ablation -- MR Imaging after TACE -- MR Imaging after Radioembolization with Yttrium-90 Microspheres -- CONCLUSION -- REFERENCES -- PART III Organ-Specific Cancers -- Chapter 9 Hepatocellular Carcinoma: Epidemiology, Pathology, Diagnosis and Screening -- EPIDEMIOLOGY, RISK FACTORS AND PREVENTION -- PATHOLOGY -- Gross Pathology -- Histology -- DIAGNOSIS -- Symptoms and Presentation -- Imaging -- Tumor Markers -- Histological Confirmation -- SCREENING -- REFERENCES -- Chapter 10 STAGING SYSTEMS FOR HEPATOCELLULAR CARCINOMA -- CHILD-TURCOTTE-PUGH NOMINAL SCORE -- OKUDA STAGING SYSTEM -- CANCER OF THE LIVER ITALIAN PROGRAM CLASSIFICATION -- BARCELONA CLINIC LIVER CANCER STAGING CLASSIFICATION -- THE CHINESE UNIVERSITY PROGNOSTIC INDEX -- LIVER CANCER STUDY GROUP OF JAPAN -- AMERICAN JOINT COMMITTEE ONCANCER/INTERNATIONAL UNIONAGAINST CANCER -- HCC STAGING SYSTEMS: A SELECTIVE REVIEW OF COMPARATIVE STUDIES -- CONCLUSION -- REFERENCES -- Chapter 11 Hepatocellular Carcinoma: Medical Management -- THE NEED FOR SYSTEMIC THERAPIES IN HEPATOCELLULAR CARCINOMA -- CYTOTOXIC CHEMOTHERAPY -- ENDOCRINE MANIPULATION -- OCTREOTIDE -- THE NEW AGE OF TARGETED THERAPIES -- TARGETED THERAPIES -- ANGIOGENESIS AND HEPATOCELLULAR CARCINOMA -- HEPATOCELLULAR CARCINOMA -- CONCLUSION -- REFERENCES -- Chapter 12 Surgical Management (Resection) -- PREOPERATIVE EVALUATION -- Patient Selection -- Evaluation of Liver Function.

Portal Vein Embolization -- SURGICAL TECHNIQUE -- MORBIDITY AND MORTALITY -- LONG-TERM OUTCOME -- REFERENCES -- Chapter 13 Liver Transplantation for Hepatocellular Carcinoma -- SELECTION CRITERIA -- LISTING FOR TRANSPLANTATION: PRIORITIZATION FOR HCC -- TUMOR PROGRESSION WHILE ON THE WAITING LIST -- LOCALIZED THERAPY FOR HCC -- EXTENDED CRITERIA GRAFTS -- LIVING DONOR LIVER TRANSPLANTATION -- POST-TRANSPLANT MANAGEMENT -- NEW FRONTIERS -- CONCLUSION -- REFERENCES -- Chapter 14 IMAGE-GUIDED ABLATION OF HEPATOCELLULAR CARCINOMA -- PRETREATMENT EVALUATION -- Imaging Assessment -- Clinical Staging -- TRIAGE OF EARLY STAGE HEPATOCELLULAR CARCINOMA -- Surgical Resection -- Liver Transplantation -- Image-guided Ablation -- CHEMICAL ABLATION -- Ethanol Injection -- Acetic Acid Injection -- THERMAL ABLATION -- Radiofrequency Ablation -- Microwave Ablation -- Laser Ablation -- CONCLUSION -- REFERENCES -- Chapter 15 EMBOLIZATION OF LIVER TUMORS: ANATOMY -- Celiac Trunk Anatomy -- Hepatic Artery Anatomy -- Non-hepatic Arteries Arising from Hepatic Arteries -- Extra-hepatic Collateral Arteries -- REFERENCES -- Chapter 16 Transcatheter Arterial Chemoembolization: Technique and Future Potential -- DEFINITION OF TACE, HISTORICAL BACKGROUND AND UNDERLYING PRINCIPLES OF TUMOR DAMAGE -- PATIENT SELECTION AND INDICATIONS FOR TACE -- CONTRAINDICATIONS FOR TACE -- PATIENT PREPARATION -- TECHNICAL CONSIDERATIONS -- TECHNIQUE -- RECOVERY -- FOLLOW-UP AND EVALUATION OF RESPONSE TO TREATMENT -- COMPLICATIONS AND SIDE EFFECTS -- SURVIVAL BENEFIT -- CURRENT RESEARCH ON TACE -- CONCLUSION -- REFERENCES -- Chapter 17 New Concepts in Targeting and Imaging Liver Cancer -- NEW CONCEPTS IN TARGETING LIVER CANCER -- Targeting Glucose Tumor Metabolism -- Targeting Malignant Stem Cells -- DRUG-ELUTING MICROSPHERES: THE NEW CONCEPT IN TACE.

NEW PERCUTANEUOUS APPROACHES FOR TREATMENT OF LIVER CANCER -- NEW APPROACHES IN IMAGING TUMOR RESPONSE AF TERTREATMENT: IMAGING BIOMARKERS -- Diffusion-weighted MR Imaging -- Dynamic Contrast-enhanced MR Imaging -- CONCLUSION -- REFERENCES -- Chapter 18 Intrahepatic Cholangiocarcinoma -- EPIDEMIOLOGY -- PATHOPHYSIOLOGY -- DIAGNOSIS -- TREATMENT -- Radiofrequency Ablation -- TACE -- REFERENCES -- CONCLUSION -- Chapter 19 Medical Management of Colorectal Liver Metastasis -- SYSTEMIC CHEMOTHERAPY IN ADVANCED COLORECTAL CANCER -- CYTOTOXIC AGENTS -- BIOLOGICAL AGENTS -- NEOADJUVANT CHEMOTHERAPY FOR COLORECTAL LIVER METASTASIS -- ADJUVANT CHEMOTHERAPY FOLLOWING HEPATIC METASTATECTOMY -- SYSTEMIC CHEMOTHERAPY IN CHEMOEMBOLIZATION -- REFERENCES -- Chapter 20 SURGICAL RESECTION OF HEPATIC METASTASES -- PRIMARY LIVER CANCER -- HEPATIC METASTASES -- SELECTING PATIENTS FOR SURGICAL RESECTION -- DEFINING RESECTABILITY IN PATIENTS WITH HEPATIC METASTASES -- TECHNIQUES FOR LIVER RESECTION -- LIVER RESECTION FOR PRIMARY LIVER CANCER -- LIVER RESECTION FOR HEPATIC COLORECTAL METASTASES -- LIVER RESECTION FOR NON-COLORECTAL METASTASES -- CONCLUSION -- REFERENCES -- Chapter 21 Clinical Management of Patients with Colorectal Liver Metastases Using Hepatic Arterial Infusion -- UNRESECTABLE DISEASE -- BORDERLINE RESECTABILITY -- ADJUVANT TREATMENT AFTER -- ADJUVANT TREATMENT AFTER RESECTION OF LIVER METASTASES -- DOSING AND ADJUSTMENT ALGORITHMS -- CONCLUSION -- REFERENCES -- Chapter 22 Colorectal Metastases: Ablation -- TECHNICAL NOTES -- RESULTS -- CONCLUSIONS -- REFERENCES -- Chapter 23 Colorectal Metastases: Chemoembolization -- PATIENT SELECTION -- CHEMOEMBOLIZATION REGIMENS -- TREATMENT -- OUTCOMES IN COLORECTAL CARCINOMA -- REFERENCES -- Chapter 24 RADIOEMBOLIZATION WITH90YTTRIUM MICROSPHERES FORCOLORECTAL LIVER METASTASES -- OVERVIEW.

PATIENT SCREENING AND SELECTION.